Robots make more business sense with AI – just don’t expect fireworks
Robot use is becoming increasingly practical, which means that such machinery is being increasingly employed – and AI can only make robotics better, as Giacomo Lee finds out.
Analysis
Robots make more business sense with AI – just don’t expect fireworks
Robot use is becoming increasingly practical, which means that such machinery is being increasingly employed...
Face recognition is just the tip of the AI Computer Vision iceberg
Flaws in AI training give as bad a name to face recognition. But as Giacomo...
Virtual therapy: Health tech at-a-distance will outlast the Covid status quo
Acceptance and resistance to digital health technologies has been a common problem across the health...
Chatbots: AI tech can be useful in real-world business applications right now
Chatbots, like AI, may seem terribly modern, but in fact have a long history –...
Bedside manner: These robots want to know how we are today
Whether dealing with a public or private provider, today's health care consumers may not be surprised to find themselves conversing with tech: with chatbots and smart assistants. While some surgical…
Quantum computers, here but not here – what businesses need to know
The future may see us living on Mars, paying for everything with crypto, and relaxing or working as we travel effortlessly about in our driverless cars. But there's an even…
IoT must become the Internet of Secure Things for widescale acceptance in the 5G era
As the world reopens for business, 2021 is seen as a year of cyber security catch-up for the IoT (Internet of Things) – one of many technology themes impacted by…
AI and Covid’s symbiotic relationship may make for tech’s Trojan horse
Artificial intelligence, or AI, has come into its own during the Covid-19 pandemic. But while the tech has strengthened the response to the crisis and enabled vaccine conspiracy theories to…
Roche’s Ocrevus set to top $7.6bn in sales by 2028 backed by new dosing approval
On 14 December, the US Food and Drug Administration (FDA) approved a shorter two-hour infusion time for Roche’s Ocrevus (ocrelizumab) in patients with relapsing multiple sclerosis (RMS) or primary progressive…
Why a surge in PD-1/PD-L1 targeted combination trials is shaping the future of cancer treatment
Targeting programmed cell death protein and its ligand (PD-1/PD-L1) have become the backbone of immunotherapy for cancer. In an era where there are big expectations from various immunotherapies, PD1 and…
